Adverum Biotech
Cameron Baker is a seasoned scientist with extensive experience in molecular and cell biology. Currently serving as a Senior Scientist at Adverum Biotechnologies, Inc. since October 2019, Cameron focuses on research and novel vector technology. Prior experience includes a role as a Scientist at Benitec Biopharma Ltd, where Cameron identified disease targets and designed therapeutics utilizing ddRNAi technology. Cameron's academic background comprises a PhD in Molecular and Cell Biology from the University of California, Berkeley, and a BA in Biochemistry from Scripps College. Early research experience includes roles at UCLA investigating neurodevelopmental disorders, at UC Berkeley studying ion homeostasis in retinal cells, and at UCSF researching cancer cell transitions, alongside developing vaccine candidates for rotavirus during undergraduate studies.
Adverum Biotech
9 followers
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.